GP与SOX化疗方案治疗三阴性乳腺癌晚期患者的临床效果比较  

Comparison of Clinical Efficacy of GP and SOX Chemotherapy in the Treatment ofAdvanced Triple-negative Breast Cancer

作　　者：丁权 朱燊 黄涛 DING Quan;ZHU Shen;HUANG Tao(Zhumadian First People's Hospital,Zhumadian,463000)

机构地区：[1]河南省驻马店市第一人民医院,463000

出　　处：《实用癌症杂志》2021年第5期800-802,835,共4页The Practical Journal of Cancer

摘　　要：目的比较吉西他滨联合顺铂(GP)与替吉奥联合奥沙利铂(SOX)化疗方案治疗三阴性乳腺癌晚期患者的临床疗效。方法收集接受GP化疗方案治疗的58例三阴性乳腺癌晚期患者研究资料,将其纳入对照组;收集同期接受SOX化疗方案治疗的60例三阴性乳腺癌晚期患者研究资料,将其纳入观察组。治疗3个疗程后,对比2组近期临床疗效,并观察2组癌胚抗原(CEA)、糖类抗原153(CA153)水平,同时记录2组不良反应情况。随访1年,统计2组生存情况。结果观察组近期临床疗效(30.00%)与对照组(27.59%)比较,差异无统计学意义(P>0.05)。治疗3个疗程后,2组CEA、CA153水平均低于治疗前(P<0.05),但组间比较,差异无统计学意义(P>0.05);2组恶性呕吐、腹泻、肝肾功能不全、白细胞减少不良反应比较,差异亦无统计学意义(P>0.05)。随访1年结果显示,2组生存情况比较,差异无统计学意义(P>0.05)。结论GP与SOX方案在三阴性乳腺癌晚期患者治疗中效果相当,均可有效降低患者CEA、CA153水平,不良反应均可耐受,生存情况无明显差异。Objective To compare the clinical efficacy of gemcitabine combined with cisplatin(GP)and tigeo combined with oxaliplatin(SOX)chemotherapy in the treatment of advanced triple-negative breast cancer.Methods Clinical data of 58 patients with advanced triple-negative breast cancer who were treated with GP chemotherapy were collected,and included them in the control group.The research data of 60 patients with advanced triple-negative breast cancer who were treated with SOX chemotherapy during the same period were collected,and included them in the observation group.After three courses of treatment,the recent clinical efficacy of the 2 groups was compared,and the levels of cancer antigen(CEA)and carbohydrate antigen 153(CA153)in the two groups were observed,and the side effects of the 2 poisons were recorded.Followed up for 1 year and counted the survival of the two groups.Results Compared with the the clinical efficacy of(27.59%)in the control group,the clinical efficacy of(30.00%)in the observation group,the difference was not statistically significant(P>0.05);after 3 courses of treatment,the levels of CEA and CA153 in the 2 groups were lower than before treatment(P<0.05),but there was no statistically significant difference between the 2 groups(P>0.05);compared malignant vomiting,diarrhea,liver and kidney dysfunction,and leukopenia between the 2 groups,there was no significant difference(P>0.05);The results of 1-year follow-up showed that there was no statistically significant difference in survival between the 2 groups(P>0.05).Conclusion GP and SOX chemotherapy are equally effective in patients with advanced triple-negative breast cancer,they both can effectively reduce the levels of CEA and CA153 in patients,their adverse reactions can be tolerated,and there is no significant difference in survival condition.

关 键 词：三阴性乳腺癌 吉西他滨 顺铂 替吉奥 奥沙利铂 

分 类 号：R737.9[医药卫生—肿瘤]